Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

F Loupakis; C Cremolini; A Fioravanti; P Orlandi; L Salvatore; G Masi; T Di Desidero; B Canu; M Schirripa; P Frumento; A Di Paolo; R Danesi; A Falcone; G Bocci

首页> 外文期刊>British Journal of Cancer >Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

【24h】

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

机译：一线FOLFOXIRI加贝伐单抗方案在转移性结直肠癌中的药效学和药理学血管生成相关标志物

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC).

机译：背景：鉴定预测或监测贝伐单抗（BV）疗效的分子和遗传标记物是转移性结直肠癌（mCRC）治疗中的关键问题。

著录项

来源
《British Journal of Cancer》 |2011年第8期|共8页
作者
F Loupakis; C Cremolini; A Fioravanti; P Orlandi; L Salvatore; G Masi; T Di Desidero; B Canu; M Schirripa; P Frumento; A Di Paolo; R Danesi; A Falcone; G Bocci;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52. [J] . Bruera G, Ricevuto E Expert opinion on biological therapy . 2011,第6期

机译：转移性大肠癌的强化化疗：在安全性和临床疗效之间进行权衡：Masi G，Loupakis F，Salvatore L等的评估。贝伐单抗联合FOLFOXIRI（伊立替康，奥沙利铂，氟尿嘧啶和亚叶酸酯）作为转移性结直肠癌的一线治疗：一项2期试验。 Lancet Oncol 2010; 11：845-52。
2. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials [J] . Cremolini C., Loupakis F., Masi G., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第5期

机译：FOLFOXIRI或FOLFOXIRI加贝伐单抗作为转移性结直肠癌的一线治疗：来自两项随机临床试验的倾向评分调整分析
3. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial [J] . Cremolini Chiara, Malmorino Federica, Bergamo Francesca, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：第II期随机研究用Bevacizumab或Bevacizumab加上一流诱导叶昔昔昔单乳蛋白酶转移结直肠癌患者的牛伐单抗和贝伐单抗化疗研究：MOMA试验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship for the matrix metalloproteinase inhibitory effect of COL-3 following oral administration to patients with refractory metastatic cancer. [D] . Rudek, Michelle Ann. 2001

机译：口服给予难治性转移癌患者后，COL-3对基质金属蛋白酶抑制作用的药代动力学与药效关系的评价。
6. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer [O] . F Loupakis, C Cremolini, A Fioravanti, 2011

机译：一线FOLFOXIRI加贝伐单抗方案在转移性结直肠癌中的药效学和药理学血管生成相关标志物
7. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer [O] . F. LOUPAKIS, C. CREMOLINI, A. FIORAVANTI, 2011

机译：一线FOLFOXIRI加贝伐单抗方案在转移性结直肠癌中的药效学和药理学血管生成相关标志物

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅